Multiple Sclerosis | Current Treatment | US | 2016
Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and convenience. In just the past five years, six new MS DMTs have launched—one infusion, three injectable, and two oral—drastically altering physician prescribing practices and preferences. The Multiple Sclerosis | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Multiple Sclerosis | Current Treatment | US presents a snapshot of how U.S. neurologists are prescribing current DMTs and insight into the factors driving their prescribing habits.
Related Market Assessment Reports
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
